Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06472713 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 13, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 1, 2024 to Jul 20, 2024
    • Interventions: Mitoxantrone hydrochloride liposome injection (Drug) to Mitoxantrone hydrochloride liposome injection (Drug), PD-1 Inhibitors (Drug)
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with PD-1 blockade in patients with recurrent (not unable to locally curative treatment) or metastatic NPC who failed at least first-line platinum-containing standard regimen and/or anti PD-1/L1.
Trial Details
NCT Number NCT06472713
Lead Sponsor Ming-Yuan Chen
Conditions
(from sponsor)		 Recurrent or Metastatic Nasopharyngeal Carcinoma
Related terms Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov